IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
Brief description of study
The purpose of this study is to study a new radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body to see how it is taken up in the body and the brain using an imaging procedure called Positron Emission Tomography (PET/CT). Imaging PARP-1 activity in various cancers may help researchers to better understand it’s function and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.
Detailed description of study
Participants will undergo up to three [18F]FTT PET/CT scans. A baseline scan will be done prior to starting therapy. A second PET/CT scan may be done 1-21 days after initiation of therapy to collect pilot data on the changes in FTT uptake with therapy. A third FTT scan may be performed when the patient progresses on therapy (e.g. PARP inhibitor). For each PET/CT imaging session, participants will undergo a static skull base to mid-thigh scan starting approximately 60 minutes post injection of [18F]FTT.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
GYNECOLOGICAL CANCER
-
Gender: Female
Patients may participate in this study if they are at least 18 years of age with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer may be eligible for this study.
Updated on
09 Mar 2024.
Study ID: 833685
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
